Verona Pharma has made significant progress over the last eighteen months reporting unequivocally positive results from all three parts of its Phase I/IIa trial of RPL554 in healthy subjects and COPD, positive headline data from its dose ranging Phase IIa trial of RPL554 in asthma patients and stellar results from its ‘add-on’ Phase IIa trial with RPL554 in COPD patients. The compound continues to demonstrate an attractive profile with its combined bronchodilator and anti-inflammatory properties ....
